Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meeting, 13495 [2018-06259]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 61 / Thursday, March 29, 2018 / Notices
licensing in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Technology description
follows.
sradovich on DSK3GMQ082PROD with NOTICES
Lentiviral Protein Delivery System for
RNA-Guided Genome Editing
Description of Technology: This
invention provides an HIV–1-based
lentiviral vector system for gene
correction strategies involving a
homologous recombination with a
variation of the CRISPR/Cas9 system.
Such systems are being explored as
potential therapies for certain hereditary
diseases. This system comprises (a) a
lentivirus vector particle comprising a
lentiviral genome which encodes at
least one guide RNA sequence that is
complementary to a first DNA sequence
in a host cell genome, (b) a Cas9 protein,
and optionally (c) a donor nucleic acid
molecule comprising a second DNA
sequence. In addition, the invention
provides a host cell comprising the
foregoing system, as well as a method of
altering a DNA sequence in a host cell
comprising contacting a host cell with
the foregoing system. Alternatively, the
invention also provides a fusion protein
comprising a Cas9 protein and a
cyclophilin A (CypA) protein, wherein
the fusion protein binds to the lentivirus
vector particle, as well as a lentiviral
vector particle comprising such a fusion
protein. Other such lentivirus-based
vectors encode a guide RNA, which
contains a specific sequence that
recognizes a target gene, and a Cas9
endonuclease, which cuts at the specific
site. However, such systems present
some problems due to constitutive
expression of Cas9 endonuclease in
lentiviral vector-transduced cells and
the large size of the Cas9 gene. The
variation of this invention delivers the
Cas9 endonuclease directly, instead of
the gene encoding the protein.
Potential Commercial Applications:
Clinical trials for hereditary diseases
such as sickle-cell disease and betathalassemia are good market
opportunities. Gene correction using the
disclosed lentiviral vector system are
being tested with respect to the betaglobin gene and the BCL11A gene to
treat sickle-cell disease and will be used
for induced pluripotent stem cell (iPS)
generation.
Development Stage: Early-stage. In
vitro data in cell-line models available.
Inventors: Naoya Uchida, Juan J. Haro
Mora and John F. Tisdale (NHLBI).
Intellectual Property: US Application
No. 62/236,223, filed October 2, 2015
and PCT/US2016/054759, filed
VerDate Sep<11>2014
19:09 Mar 28, 2018
Jkt 244001
September 30, 2016, (NIH Reference No.
E–165–2015/0,1).
Publications: Lentiviral protein
delivery system for RNA-guided genome
editing, PCT Publication No. WO/2017/
059241, published April 6, 2017.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Denise Crooks at crooksd@
mail.nih.gov.
Dated: March 22, 2018.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2018–06364 Filed 3–28–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, NICHD.
The meeting will be open to the
public as indicated below, with the
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
Eunice Kennedy Shriver National
Institute Of Child Health And Human
Development, including consideration
of personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
13495
Name of Committee: Board of Scientific
Counselors, NICHD.
Date: June 1, 2018.
Open: 8:00 a.m. to 11:45 a.m.
Agenda: A report by the Scientific Director,
NICHD, on the status of the NICHD Division
of Intramural Research; talks by various
intramural scientists, and current
organizational structure.
Place: National Institutes of Health,
Building 31A, Conference Room 2A48, 31
Center Drive, Bethesda, MD 20892.
Closed: 11:45 a.m. to 4:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 31A, Conference Room 2A48, 31
Center Drive, Bethesda, MD 20892.
Contact Person: Constantine A. Stratakis,
MD, D(med)Sci, Scientific Director, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, NIH,
Building 31A, Room 2A46, 31 Center Drive,
Bethesda, MD 20892, 301–594–5984,
stratakc@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/meetings/Pages/
index.aspx, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos.93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: March 23, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–06259 Filed 3–28–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Board on Medical
Rehabilitation Research. The meeting
will be open to the public, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Advisory
Board on Medical Rehabilitation Research.
E:\FR\FM\29MRN1.SGM
29MRN1
]]>Agencies
[Federal Register Volume 83, Number 61 (Thursday, March 29, 2018)]
[Notices]
[Page 13495]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06259]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health and
Human Development; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Board of Scientific
Counselors, NICHD.
The meeting will be open to the public as indicated below, with the
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the Eunice
Kennedy Shriver National Institute Of Child Health And Human
Development, including consideration of personnel qualifications and
performance, and the competence of individual investigators, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Board of Scientific Counselors, NICHD.
Date: June 1, 2018.
Open: 8:00 a.m. to 11:45 a.m.
Agenda: A report by the Scientific Director, NICHD, on the
status of the NICHD Division of Intramural Research; talks by
various intramural scientists, and current organizational structure.
Place: National Institutes of Health, Building 31A, Conference
Room 2A48, 31 Center Drive, Bethesda, MD 20892.
Closed: 11:45 a.m. to 4:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 31A, Conference
Room 2A48, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Constantine A. Stratakis, MD, D(med)Sci,
Scientific Director, Eunice Kennedy Shriver National Institute of
Child Health and Human Development, NIH, Building 31A, Room 2A46, 31
Center Drive, Bethesda, MD 20892, 301-594-5984,
[email protected].
Information is also available on the Institute's/Center's home
page: https://www.nichd.nih.gov/about/meetings/Pages/index.aspx,
where an agenda and any additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos.93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: March 23, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-06259 Filed 3-28-18; 8:45 am]
BILLING CODE 4140-01-P
